Fig. 1
From: LncRNA CTD-2555A7.2 promotes bone formation with LncRNA-specific cascade amplification strategy
CTD-2555A7.2 promoted osteogenic differentiation. A,B Expression levels of CTD-2555A7.2 in 55-69 and 70-95 years old male (left) and female (right) patients with osteoporosis, as detected by RT-PCR (mean ± S.D., n > 12). 55-69: 55-69 years old osteoporosis patients. 70-95: 70-95 years old osteoporosis patients.C-E Correlation analysis between CTD-2555A7.2 level and Alp, Ocn or Sp7 mRNA levels in bone tissues from osteoporosis patients, as detected by RT-PCR.F ALP and Alizarin Red staining of hMSCs treated with CTD-2555A7.2 over-expression plasmid (compared with pCDNA3.1 plasmid), as detected by ALP staining and Alizarin Red staining (left), and Alp/Runx2 expression levels of CTD-2555A7.2 over-expression plasmid treated hMSCs, as detected by RT-PCR (right, mean ± S.D., n = 3). ALP: results of ALP staining. ARS: results of Alizarin Red staining. vector: pCDNA3.1 plasmid. CTD: CTD-2555A7.2 over-expression plasmid.G ALP and Alizarin Red staining (left), and Alp/Runx2 expression levels (right) of hMSCs treated with CTD-2555A7.2 siRNA (compared with negative control siRNA, mean ± S.D., n = 3). si-NC: negative control siRNA. si-CTD: CTD-2555A7.2 siRNA.H ALP and RUNX2 protein levels of hMSCs treated with CTD-2555A7.2 over-expression plasmid, as detected by western blot. Representative western blots visualized by enhanced chemiluminescence method (left) and the quantification results with GAPDH as internal control (right, mean ± S.D., n> 3). I. ALP and RUNX2 protein levels of hMSCs treated with CTD-2555A7.2 siRNA (right, mean ± S.D., n > 3).*P < 0.05, **P < 0.01, ***P < 0.001
